Metabolism has always been a crucial pillar in cancer treatment, but clinical considerations have been limited to general diet and nutrition advice, minimizing the potential therapeutic impact of ...

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...

WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a ...

Celcuity highlighted strong phase III second-line data for gedatolisib in PIK3CA "wild-type" HR-positive breast cancer — the ...